Back to top
more

Ligand Pharmaceuticals (LGND)

(Delayed Data from NSDQ)

$86.88 USD

86.88
215,820

+2.51 (2.97%)

Updated Jul 8, 2024 04:00 PM ET

After-Market: $86.88 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 34% (84 out of 249)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Ligand (LGND) Q4 Earnings Down Y/Y, Revenues Miss Estimates

Ligand Pharmaceuticals Incorporated (LGND) reported fourth-quarter 2016 earnings of 50 cents per share (including the impact of stock-based compensation expense), down 11.1% from the year-ago figure.

    Drug Stocks Q4 Earnings Slated for Feb 23: BMRN, ICPT & More

    The fourth-quarter earnings season is drawing to a close with results from 411 S&P 500 members or 82.2% of the index's total membership already out, as of Feb 22, 2017.

      Arpita Dutt headshot

      Forget Alexion, Buy these 4 Biotech Stocks Instead

      We advise investors to consider biotech stocks which sport a strong Zacks Rank and have interesting pipelines/products and growth potential.

        Ligand (LGND) Q4 Earnings: Will the Stock Pull a Surprise?

        Ligand Pharmaceuticals Incorporated (LGND) is scheduled to report fourth-quarter 2016 results on Feb 23, after the market closes.

          The Zacks Analyst Blog Highlights: Celgene, Exelixis, Ligand Pharmaceuticals and RedHill Biopharma

          The Zacks Analyst Blog Highlights: Celgene, Exelixis, Ligand Pharmaceuticals and RedHill Biopharma

            Ligand (LGND) Signs Licensing Deals with Ono and Novartis

            Ligand Pharmaceuticals announced that it has entered into a worldwide license agreement with Ono Pharmaceutical under which Ono will use its OmniAb platform for the discovery of fully human mono- and bispecific antibodies.